Expert Opinion On Drug Safety

Expert Opinion on Drug Safety is a peer-reviewed journal published by Taylor & Francis, established in 2002, devoted to drug safety and pharmacovigilance, with a 2025 impact factor of 3.0（Expert Opinion on Drug Safety）是由（Taylor & Francis）出版的同行评审期刊，2002 年创办，专注药物安全与药物警戒，2025 年影响因子为 3.0。

Scope

• Publishes rigorously peer-reviewed review articles on all aspects of drug safety刊载经严格同行评审、涵盖药物安全各层面的综述文章。
• Also publishes original papers on the clinical implications of drug treatment safety issues亦刊载有关药物治疗安全性问题临床影响的原创论文。
• Reviews cover the occurrence, management and prevention of drug-associated adverse events综述涵盖药物相关不良事件的发生、处理与预防。
• Includes risk-benefit analyses of individual drugs and drug classes, and comparative tolerability studies包括单个药物与药物类别的风险获益分析，以及耐受性比较研究。
• Covers pharmacovigilance and pharmacoepidemiological studies, and methods for detecting and evaluating adverse events涵盖药物警戒与药物流行病学研究，以及不良事件的识别与评价方法。

History

• Established in 2002 as part of the Expert Opinion series该刊 2002 年创办，属 Expert Opinion 系列期刊。
• It was published under the Informa healthcare imprint and is now part of Taylor & Francis该刊最初由（Informa healthcare）出版，现属（Taylor & Francis）。
• It appears monthly and is MEDLINE-indexed该刊按月出版，并被（MEDLINE）收录。
• It had a 2025 impact factor of 3.0该刊 2025 年影响因子为 3.0。

Editors

• The editor-in-chief is Roger McIntyre of the University of Toronto in Canada现任主编为加拿大（University of Toronto）的 Roger McIntyre。
• An editorial advisory board draws experts from the USA, Greece, Italy, the UK, the Netherlands, Germany and Australia编辑顾问委员会汇聚来自美国、希腊、意大利、英国、荷兰、德国与澳大利亚的专家。
• Manuscripts are peer reviewed稿件实行同行评审。
• The journal does not publish case reports, case series or animal studies该刊不刊载病例报告、病例系列或动物研究。